News
Article
Author(s):
New research reveals how low blood sugar can damage the retina in diabetes, highlighting potential treatments targeting specific proteins to prevent vision loss.
(Image credit: ©xb100/AdobeStock)
A new study found that low blood sugar (hypoglycemia) may promote a breakdown of the blood-retinal barrier – a boundary that regulate the flow of nutrients, waste and water in and out of the retina. The study was led by scientists and researchers at the Wilmer Eye Institute and Johns Hopkins Medicine and was funded by the National Institutes of Health.1
The study was a mice model and offers insight into the origin or diabetic retinopathy, specific to patients with hypoglycemic episodes. The full study was published in Science Translational Medicine in April and explains how a specific protein known as hypoxia-inducible factor (HIF) accumulates in certain cells in the retina during periods of low blood sugar.
Testing HIF’s role in hypoglycemia by inducing periods of low blood sugar in mice with and without diabetes, researchers found that mice with diabetes had higher levels of HIF during hypoglycemia that would promote the breakdown of the blood-retinal barrier, causing leakage in retinal blood vessels. Contrary, mice without diabetes did not experience higher levels of HIF.
Furthermore, the team used an experimental drug known as 32-134D, which inhibits the HIF protein. It was found that in some diabetic mice that received an injection of 32-134D prior to induced episodes of hypoglycemia, lower HIF levels were observed.
“These studies help explain why patients with diabetes who are initially started on tight glucose control, the cornerstone of diabetic management, or those with high glycemic variability (transient episodes of very low – followed by very high – serum glucose levels), experience worsening of their diabetic eye disease,” said author Akrit Sodhi, MD, PhD, associate professor of ophthalmology and the Branna and Irving Sisenwein Professor of Ophthalmology at the Johns Hopkins University School of Medicine and the Wilmer Eye Institute.
Further studies on HIF, the breakdown of the blood-retinal barrier, and 32-134D in patients with diabetic retinopathy are planned.
“Our findings underscore why therapies targeting HIF will be an effective approach to prevent or treat diabetic retinopathy,” Sodhi said.
Additional authors for this study include Chuanyu Guo, Yueqi Niu, Xuemei Pan, Deepti Sharma, Evan Lau, Yang Jin, Md Amanullah, Kevin Lo and Jiang Qian of the Wilmer Eye Institute, Johns Hopkins Medicine; Guillaume Luxardi and Ala Moshiri of the University of California, Davis; and Silvia Montaner of the University of Maryland. Xuemei Pan also has affiliations to the Shandong University of Traditional Chinese Medicine.
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.